DE3743936C2 - - Google Patents
Info
- Publication number
- DE3743936C2 DE3743936C2 DE3743936A DE3743936A DE3743936C2 DE 3743936 C2 DE3743936 C2 DE 3743936C2 DE 3743936 A DE3743936 A DE 3743936A DE 3743936 A DE3743936 A DE 3743936A DE 3743936 C2 DE3743936 C2 DE 3743936C2
- Authority
- DE
- Germany
- Prior art keywords
- glu
- mixture
- peptides
- general formula
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- 230000000078 anti-malarial effect Effects 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 238000006068 polycondensation reaction Methods 0.000 claims description 7
- 239000003430 antimalarial agent Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 3
- 239000003929 acidic solution Substances 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- 239000011347 resin Substances 0.000 description 22
- 229920005989 resin Polymers 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 11
- 201000004792 malaria Diseases 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 244000045947 parasite Species 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000003936 merozoite Anatomy 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 4
- -1 4-nitrophenyl ester Chemical class 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229920006122 polyamide resin Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 2
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 241000256186 Anopheles <genus> Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SGRUYHPEDOEJCU-UHFFFAOYSA-N (2-oxo-5,5-diphenyl-1,3-oxazol-4-yl) dihydrogen phosphate Chemical compound C1=CC=C(C=C1)C2(C(=NC(=O)O2)OP(=O)(O)O)C3=CC=CC=C3 SGRUYHPEDOEJCU-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- ZKDXHLFLKKWCBY-UHFFFAOYSA-N 4-Hydroxymethyl-3-methoxyphenoxyacetic acid Chemical compound COC1=CC(OCC(O)=O)=CC=C1CO ZKDXHLFLKKWCBY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- WLHBRQYVZLNQFE-UHFFFAOYSA-N O[S+]1C2=CC=CC=C2N=C1 Chemical compound O[S+]1C2=CC=CC=C2N=C1 WLHBRQYVZLNQFE-UHFFFAOYSA-N 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- RBNPZEHAODHBPZ-UHFFFAOYSA-M dihydroxyaluminium Chemical compound O.O.NCC(=O)O[Al] RBNPZEHAODHBPZ-UHFFFAOYSA-M 0.000 description 1
- ASMQGLCHMVWBQR-UHFFFAOYSA-M diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)([O-])OC1=CC=CC=C1 ASMQGLCHMVWBQR-UHFFFAOYSA-M 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8622820A IT1213576B (it) | 1986-12-23 | 1986-12-23 | Composizione polipeptidica utile per la preparazione di vaccini antimalaria e di kits diagnostici per la determinazione di anticorpi antimerozoite. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3743936A1 DE3743936A1 (de) | 1988-07-07 |
| DE3743936C2 true DE3743936C2 (https=) | 1991-06-06 |
Family
ID=11200817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873743936 Granted DE3743936A1 (de) | 1986-12-23 | 1987-12-23 | Polypeptid-zusammensetzung, die fuer die herstellung von antimalaria-vakzinen und diagnostischen ausruestungen fuer den nachweis von antimerozoit-antikoerpern nuetzlich ist |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5118501A (https=) |
| AR (1) | AR240254A1 (https=) |
| AT (1) | ATA339087A (https=) |
| BE (1) | BE1001385A3 (https=) |
| CA (1) | CA1301065C (https=) |
| CH (1) | CH672490A5 (https=) |
| DE (1) | DE3743936A1 (https=) |
| ES (1) | ES2008794A6 (https=) |
| FR (1) | FR2608925B1 (https=) |
| GB (1) | GB2199326B (https=) |
| GR (1) | GR871992B (https=) |
| IT (1) | IT1213576B (https=) |
| NL (1) | NL8703101A (https=) |
| OA (1) | OA08704A (https=) |
| SE (1) | SE468597B (https=) |
| ZA (1) | ZA879622B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005607A1 (en) * | 1986-03-14 | 1987-09-24 | Saramane Pty. Ltd.; | Polypeptides providing protective immunity against malaria |
| GB8819209D0 (en) * | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2145092B (en) * | 1983-01-28 | 1988-04-07 | Univ New York | Protective peptide antigen |
| IL76338A (en) * | 1984-09-11 | 1994-08-26 | Saramane Pty Ltd | Plasmodium plasmodium immunogenic polypeptides, AND molecules encoding them, a method for preparing the polypeptides and preparations containing the polypeptide |
| WO1987005607A1 (en) * | 1986-03-14 | 1987-09-24 | Saramane Pty. Ltd.; | Polypeptides providing protective immunity against malaria |
| DE3621719A1 (de) * | 1986-06-28 | 1988-01-14 | Roehm Gmbh | Verfahren zur ausloesung der bildung von antikoerpern |
-
1986
- 1986-12-23 IT IT8622820A patent/IT1213576B/it active
-
1987
- 1987-12-18 SE SE8705073A patent/SE468597B/sv unknown
- 1987-12-21 CH CH5002/87A patent/CH672490A5/it not_active IP Right Cessation
- 1987-12-22 NL NL8703101A patent/NL8703101A/nl not_active Application Discontinuation
- 1987-12-22 GR GR871992A patent/GR871992B/el unknown
- 1987-12-22 AT AT0339087A patent/ATA339087A/de not_active Application Discontinuation
- 1987-12-22 ZA ZA879622A patent/ZA879622B/xx unknown
- 1987-12-23 ES ES8800194A patent/ES2008794A6/es not_active Expired
- 1987-12-23 DE DE19873743936 patent/DE3743936A1/de active Granted
- 1987-12-23 CA CA000555291A patent/CA1301065C/en not_active Expired - Lifetime
- 1987-12-23 FR FR878718091A patent/FR2608925B1/fr not_active Expired - Lifetime
- 1987-12-23 OA OA59254A patent/OA08704A/xx unknown
- 1987-12-23 GB GB8729976A patent/GB2199326B/en not_active Expired - Lifetime
- 1987-12-23 BE BE8701476A patent/BE1001385A3/fr not_active IP Right Cessation
- 1987-12-23 AR AR309698A patent/AR240254A1/es active
-
1989
- 1989-12-20 US US07/456,220 patent/US5118501A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE3743936A1 (de) | 1988-07-07 |
| GR871992B (en) | 1988-03-23 |
| ATA339087A (de) | 1996-08-15 |
| ZA879622B (en) | 1988-08-31 |
| SE8705073L (sv) | 1988-06-24 |
| GB2199326B (en) | 1990-11-14 |
| FR2608925A1 (fr) | 1988-07-01 |
| FR2608925B1 (fr) | 1990-05-18 |
| AR240254A1 (es) | 1990-03-30 |
| OA08704A (en) | 1989-03-31 |
| IT1213576B (it) | 1989-12-20 |
| US5118501A (en) | 1992-06-02 |
| CA1301065C (en) | 1992-05-19 |
| SE8705073D0 (sv) | 1987-12-18 |
| NL8703101A (nl) | 1988-07-18 |
| CH672490A5 (https=) | 1989-11-30 |
| IT8622820A0 (it) | 1986-12-23 |
| ES2008794A6 (es) | 1989-08-01 |
| SE468597B (sv) | 1993-02-15 |
| GB8729976D0 (en) | 1988-02-03 |
| BE1001385A3 (fr) | 1989-10-17 |
| GB2199326A (en) | 1988-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69017149T2 (de) | Synthetische Peptide nützlich als universale Träger für die Herstellung von immunogenischen Konjugaten und deren Benützung in der Entwicklung von synthetischen Impfstoffen. | |
| DE68907045T2 (de) | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. | |
| DE3881204T2 (de) | Moleküle mit mindestens einer peptidsequenz einer oder mehrerer epitopen eines p.falciparum-produzierten proteins in hepatozyten und zusammensetzungen davon. | |
| DE69333468T2 (de) | Schützende antikörper induzierende antigene aus plasmodium falciparum | |
| DE69229107T2 (de) | Peptidsequenzen, spezifisch für die hepatitische phase von p. falciparum, epitope tragend; die die fähigkeit besitzen, die t-lymphozyten anzuregen | |
| DE3486159T2 (de) | Schuetzendes peptid-antigen. | |
| DE69635077T2 (de) | Gegen malaria polypeptidische molekulen von vorerythrozytären stadium | |
| DE3685917T2 (de) | Peptid-zusammensetzung fuer die herstellung von malaria-impfstoff, sowie fuer die vorbereitung von diagnostischen einzelteilen fuer den nachweis von malaria-aehnlichen krankheiten. | |
| DE69020755T3 (de) | Physiologisch aktives Polypeptid und DNA. | |
| DE1951256C3 (de) | Verfahren zur Herstellung eines formalinisierten Allergens und dieses Allergen enthaltende Mitte! | |
| DE3741183C2 (https=) | ||
| DE69630583T2 (de) | Peptide, bronchodilator und den blutstrom verbesserndes mittel | |
| US4735799A (en) | Malaria vaccine | |
| DE69115539T2 (de) | Immunologische Komponente, Verfahren zur Synthese und Verwendung in Anit-Malaria-Impfstoff-Zusammensetzungen | |
| DE3743936C2 (https=) | ||
| DE60205907T2 (de) | Hypoallergene Impfstoffe gegen Allergie basierend auf Lieschgraspollenallergen Phl p 7 | |
| EP0338437B1 (de) | Synthetische Vakzine gegen die Maul- und Klauenseuche und Verfahren zu deren Herstellung | |
| DE3587503T2 (de) | Antigene aus plasmodium-falciparum. | |
| DE69518764T2 (de) | Peptide mit entzündungshemmende aktivität | |
| DE69133208T2 (de) | Vier-aminosäurenepitop mit schutzwirkung gegen plasmodium vivax malaria | |
| DE3723583C2 (https=) | ||
| DE60033783T2 (de) | Regulatorische/entfaltende peptide von ezrin | |
| EP0315085B1 (de) | Rekombinantes histidinreiches Protein von Plasmodium falciparum, seine Herstellung und Verwendung | |
| DE68913273T2 (de) | CRF vom Fisch. | |
| CH645880A5 (de) | Synthetisches antigenaktives polypeptid, verfahren zu dessen herstellung und das polypeptid enthaltendes antigenes mittel sowie arzneimittel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |